REG - Optima Health PLC - Full Year Trading Update

Optima HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260417:nRSQ9162Aa&default-theme=true

RNS Number : 9162A  Optima Health PLC  17 April 2026

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment)
(EU Exit) Regulations 2019/310. Upon the publication of this announcement via
Regulatory Information Service, this inside information is now considered to
be in the public domain.

17 April 2026

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

Full Year Trading Update

Full year adjusted EBITDA expected to be c.10% ahead of market expectations

Optima Health (AIM: OPT), the UK's leading provider of technology enabled
corporate health and wellbeing solutions, today announces an unaudited trading
update for the year ended 31 March 2026.

Further to the previously communicated commentary on current trading announced
on 31 March 2026, Optima now expects FY26 Adjusted EBITDA to be ahead of
market expectations 1  (#_ftn1) by c.10%.

Optima has continued to make strong progress against its strategic objectives
and medium-term targets of £200 million revenue and £40 million adjusted
EBITDA. The recent acquisition of PAM, which completed on 26 March 2026,
positions the enlarged Group to capitalise on the growing market opportunity,
whilst benefiting from significant operational and cost synergies which will
help Optima achieve its medium-term EBITDA target.

The previously disclosed procurement matter has now been settled. Other
operating income of £2.3 million was recognised in H1 FY26, and a further
£2.4 million has been recognised in H2 FY26.

A full trading update will be made later in Q2 2026.

Jonathan Thomas, Chief Executive Officer, said: "Optima's strong financial
performance in H2, ahead of market expectations, reflects the consistent
progress we have continued to make against our strategic objectives. The
recent transformational acquisition of PAM has further solidified Optima's
position in the attractive and growing occupational health market. We look
forward to increasing our presence in our core markets, alongside seeking new
opportunities, as we continue to accelerate growth."

 

  Enquiries

 Optima Health                                       +44(0)3300085113

 Jonathan Thomas, CEO                                media@OptimaHealth.co.uk

 Heidi Giles, CFO

 Panmure Liberum Limited                             +44 (0)20 3100 2000

 Nominated Adviser and Corporate Broker

 Emma Earl / Will Goode/ Mark Rogers

 Rupert Dearden

 Cavendish Capital Markets                           + 44 (0)20 7220 0500

 Joint Broker

 Geoff Nash/Ben Jeynes/George Lawson

 Julian Morse/Michael Johnson/Nigel Birks

 ICR Healthcare                                      optimahealth@icrinc.com

 UK Financial PR Adviser

 Mary-Jane Elliott / Angela Gray / Lindsey Neville

 

About Optima Health

Optima Health is the UK's leading provider of occupational health and
wellbeing services, delivering clinically led, technology-driven solutions to
organisations across the public and private sectors. With a team of more than
2,000 including 1,250 clinicians, Optima Health supports millions of employees
and operates from a network of more than 50 clinics nationwide.

 In addition to its core UK market, Optima Health also operates
in Ireland under Optima Health Ireland, providing occupational health
services to clients nationwide.

 

For more information visit www.optimahealth.co.uk
(http://www.optimahealth.co.uk/)

 

 1  (#_ftnref1) FY26 adjusted EBITDA market consensus £18.1 million

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTUBVVRNRUSARR



            Copyright 2019 Regulatory News Service, all rights reserved